Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum - PubMed (original) (raw)
Sanjay Kaul 2, Hertzel C Gerstein 3, Rury R Holman 4, Bernard Zinman 5, Jay S Skyler 6, Jennifer B Green 7, John B Buse 8, Silvio E Inzucchi 9, Lawrence A Leiter 10, Itamar Raz 11, Julio Rosenstock 12, Matthew C Riddle 13
Affiliations
- PMID: 29263194
- PMCID: PMC5741160
- DOI: 10.2337/dci17-0057
Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum
William T Cefalu et al. Diabetes Care. 2018 Jan.
Abstract
In December 2008, the U.S. Food and Drug Administration issued guidance to the pharmaceutical industry setting new expectations for the development of antidiabetes drugs for type 2 diabetes. This guidance expanded the scope and cost of research necessary for approval of such drugs by mandating long-term cardiovascular outcomes trials (CVOTs) for safety. Since 2008, 9 CVOTs have been reported, 13 are under way, and 4 have been terminated. Reassuringly, each of the completed trials demonstrated the noninferiority of their respective drugs to placebo for their primary cardiovascular (CV) composite end point. Notably, four additionally provided evidence of CV benefit in the form of significant decreases in the primary CV composite end point, two suggested reductions in CV death, and three suggested reductions in all-cause mortality. Although these trials have yielded much valuable information, whether that information justifies the investment of time and resources is controversial. In June 2016, a Diabetes Care Editors' Expert Forum convened to review the processes and challenges of CVOTs, discuss the benefits and limitations of their current designs, and weigh the merits of modifications that might improve the efficiency and clinical value of future trials. Discussion and analysis continued with the CVOT trial results released in June 2017 at the American Diabetes Association's Scientific Sessions and in September 2017 at the European Association for the Study of Diabetes scientific meeting. This article summarizes the discussion and findings to date.
© 2017 by the American Diabetes Association.
Figures
Figure 1
Completed and ongoing CVOTs (–,,–58). 3-P, 3-point; 4-P, 4-point; 5-P, 5-point. DECLARE-TIMI 58, Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events; ESRD, end-stage renal disease; HARMONY Outcomes, Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus; PIONEER 6, A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes; REWIND, Researching Cardiovascular Events With a Weekly Incretin in Diabetes; VERTIS CV, Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease.
Similar articles
- Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
Yandrapalli S, Jolly G, Horblitt A, Sanaani A, Aronow WS. Yandrapalli S, et al. Postgrad Med. 2017 Nov;129(8):811-821. doi: 10.1080/00325481.2017.1358064. Epub 2017 Jul 27. Postgrad Med. 2017. PMID: 28749197 Review. - Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
Scheen AJ. Scheen AJ. Circ Res. 2018 May 11;122(10):1439-1459. doi: 10.1161/CIRCRESAHA.117.311588. Circ Res. 2018. PMID: 29748368 Free PMC article. Review. - Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression.
Maiorino MI, Longo M, Scappaticcio L, Bellastella G, Chiodini P, Esposito K, Giugliano D. Maiorino MI, et al. Cardiovasc Diabetol. 2021 Oct 18;20(1):210. doi: 10.1186/s12933-021-01401-8. Cardiovasc Diabetol. 2021. PMID: 34663316 Free PMC article. - EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Schernthaner G, Schernthaner-Reiter MH, Schernthaner GH. Schernthaner G, et al. Clin Ther. 2016 Jun;38(6):1288-1298. doi: 10.1016/j.clinthera.2016.04.037. Epub 2016 May 19. Clin Ther. 2016. PMID: 27210264
Cited by
- Glycaemic control is still central in the hierarchy of priorities in type 2 diabetes management.
Khunti K, Zaccardi F, Amod A, Aroda VR, Aschner P, Colagiuri S, Mohan V, Chan JCN. Khunti K, et al. Diabetologia. 2024 Aug 19. doi: 10.1007/s00125-024-06254-w. Online ahead of print. Diabetologia. 2024. PMID: 39155282 - Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists.
Liu QK. Liu QK. Front Endocrinol (Lausanne). 2024 Jul 24;15:1431292. doi: 10.3389/fendo.2024.1431292. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39114288 Free PMC article. Review. - Methodology of clinical trials on sodium-glucose cotransporter 2 inhibitors registered on ClinicalTrials.gov: a cross-sectional study.
Šaler F, Viđak M, Puljak L. Šaler F, et al. BMC Med Res Methodol. 2024 Jul 30;24(1):164. doi: 10.1186/s12874-024-02292-5. BMC Med Res Methodol. 2024. PMID: 39080564 Free PMC article. - GLP-1 Receptor Agonists and Cardiovascular Disease: What Do Clinicians Need to Know?
Hayat J, Shah NP, Agarwala A, Khan MS, Butler J. Hayat J, et al. Curr Atheroscler Rep. 2024 Aug;26(8):341-351. doi: 10.1007/s11883-024-01214-6. Epub 2024 May 29. Curr Atheroscler Rep. 2024. PMID: 38809399 Review. - Comparative effect of physical health training and psychological training of the theory of reasoned action (TRA) model on the life quality of patients with diabetes in Tehran, Iran: utilization of message texting.
Sadeghi D, Motlagh MK, Darvish A, Daryaafzoon M, Mohamadnejad E, Molaei A, Montazerlotf P, Hosseini RSS. Sadeghi D, et al. BMC Endocr Disord. 2024 May 15;24(1):69. doi: 10.1186/s12902-024-01598-1. BMC Endocr Disord. 2024. PMID: 38745189 Free PMC article.
References
- U.S. Food and Drug Administration. Guidance for industry: diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes [Internet]. Available from www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid.... Accessed 31 October 2016
- Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457–2471 - PubMed
- Caveney E, Turner JR. White paper. A review of FDA guidance: understanding the FDA guidance on assessing cardiovascular risks for new antidiabetic therapies [Internet]. Available from http://www.quintiles.com/library/white-papers/new-fda-guidance-on-antidi.... Accessed 31 October 2016
- European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus [Internet], 2012. Available from http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guidelin.... Accessed 3 November 2016
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical